EGFR and lung adenocarcinoma: While several studies have reported an association between high PD-L1 expression and poorer progression-free survival (PFS) following EGFR-TKI treatment in patients with EGFR-mutated lung adenocarcinoma,7 its relationship with overall survival (OS), particularly in those receiving first-line osimertinib, is yet to be clearly established.